CompletedPhase NA

Glucagon Like Peptide-1 in Remote Ischemic Conditioning

The Role of Glucagon Like Peptide-1 in the Protective Effect of Remote Ischemic Conditioning During Ischemia-reperfusion

Lead sponsor

Karolinska Institutet

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•Male•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02746757

Org study IDRIPC GLP-1

Timeline

Milestones

Study first posted2016-04-21estimated

Last update posted2018-03-07actual

Study start2015-05actual (month precision)

Primary completion2017-12actual (month precision)

Study completion2018-01actual (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

Healthy male volunteers -

Exclusion criteria

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.